A Phase II, long-term, extension study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225225

Enrollment

Registered

2020-06-11

Start date

2020-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne muscular dystrophy

Interventions

investigational material(s) Generic name etc : DS-5141b INN of investigational material : renadirsen Therapeutic category code : 49- Other agents affecting cellular function Dosage and Administration

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Has competed a study of DS5141-A-J101.

Exclusion criteria

Exclusion criteria: 1) Significant safety issues in a study of DS5141-A-J101 2) Patient who does not consent to use appropriate contraception 3) Patient who was judged by the investigator that is not appropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
safety efficacy Adverse events, Laboratory tests, etc. Motor function, Respiratory function, Cardiac function, Quantitative muscle strength evaluation	—

Secondary

Measure	Time frame
pharmacokinetics plasma concentration of DS-5141a	—

Countries

Japan

Contacts

Public ContactContact for Clinical Trial Information

DAIICHI SANKYO Co.,Ltd.

dsclinicaltrial_jp@daiichisankyo.com+81-3-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026